TMO's Growth Comparisons in II. Quarter 2026
Thermo Fisher Scientific Inc improved it's Revenue by 10.49% year on year in the second quarter 2026, and outpaced the 9.47% growth in the Scientific & Technical Instruments industry, but Thermo Fisher Scientific Inc 's growth compares unfavorably, to the 26.05% Revenue increase in the Technology sector.
Comparing the company's Revenue to the first quarter results, sales were higher by 8.99% . On the yearly basis, average annual sales growth for Thermo Fisher Scientific Inc is 6.7%, while S & P 500's including only Businesses with the second quarter 2026 earnings, average annual sales growth is 10.59% over the past five years.
| Segment Name |
Y / Y |
Sequential |
| Life Sciences Solutions |
|
12.6 % |
- |
| Analytical Instruments |
|
-0.12 % |
- |
| Specialty Diagnostics |
|
-0.52 % |
- |
| Specialty Diagnostics IntersubEliminations |
|
- |
- |
| Laboratory Products and Biopharma Services |
|
7.02 % |
- |
| Laboratory Products and Biopharma Services IntersubEliminations |
|
- |
- |
| Total Reportable Segments |
|
6.3 % |
- |
| Total Reportable Life Sciences Solutions |
|
12.6 % |
- |
| Total Reportable Life Sciences Solutions Biosciences |
|
-1.21 % |
- |
| Total Reportable Life Sciences Solutions Genetic sciences |
|
-3.25 % |
- |
| Total Reportable Life Sciences Solutions BioProduction |
|
33.08 % |
- |
| Total Reportable Life Sciences Solutions Other |
|
- |
- |
| Total Reportable Analytical Instruments |
|
-0.12 % |
- |
| Total Reportable Analytical Instruments Chromatography and mass spectrometry |
|
3.23 % |
- |
| Total Reportable Analytical Instruments Chemical analysis |
|
-0.35 % |
- |
| Total Reportable Analytical Instruments Electron microscopy |
|
-3.95 % |
- |
| Total Reportable Specialty Diagnostics |
|
-0.52 % |
- |
| Total Reportable Specialty Diagnostics Clinical diagnostics |
|
3.04 % |
- |
| Total Reportable Specialty Diagnostics ImmunoDiagnostics |
|
5.99 % |
- |
| Total Reportable Specialty Diagnostics Microbiology |
|
5.26 % |
- |
| Total Reportable Specialty Diagnostics Transplant diagnostics |
|
7.08 % |
- |
| Total Reportable Specialty Diagnostics Healthcare market channel |
|
-9.28 % |
- |
| Total Reportable Laboratory Products and Biopharma Services |
|
7.02 % |
- |
| Total Reportable Laboratory Products and Biopharma Services Laboratory products |
|
-2.23 % |
- |
| Total Reportable Laboratory Products and Biopharma Services Research and safety market channel |
|
5.79 % |
- |
| Total Reportable Laboratory Products and Biopharma Services Pharma services |
|
8.34 % |
- |
| Total Reportable Laboratory Products and Biopharma Services Clinical research |
|
9.75 % |
- |
| Elimination of interrevenues |
|
- |
- |
| North America |
|
3.48 % |
- |
| Europe |
|
12.69 % |
- |
| Asia-Pacific |
|
4.18 % |
- |
| Other regions |
|
10.39 % |
- |
| Consumables |
|
8.45 % |
- |
| Instruments |
|
-4.37 % |
- |
| Services |
|
7.85 % |
- |
| Reconciling Items |
|
8.71 % |
- |
| Reconciling Items Life Sciences Solutions |
|
7.75 % |
- |
| Reconciling Items Analytical Instruments |
|
19.51 % |
- |
| Reconciling Items Specialty Diagnostics |
|
0 % |
- |
| Reconciling Items Laboratory Products and Biopharma Services |
|
10.81 % |
- |
| Total |
|
6.18 % |
- |
Comparing 9.35% year on year bottom-line growth in the second quarter, Thermo Fisher Scientific Inc grew on the lower pace than the 9.38% growth in the Scientific & Technical Instruments industry and 82.95% EPS rise in the Technology sector. Slow second quarter income per share, in Scientific & Technical Instruments industry and Technology sector, were portrayed in Thermo Fisher Scientific Inc results which underperformed overall market.
Comparing company's EPS to the first quarter results, income per share were higher by 5.64% . On the yearly basis, average annual income per share growth for Thermo Fisher Scientific Inc is 2.14%, while S & P 500's including only the businesses with the second quarter 2026 Results, average annual income per share growth is 22.96% over the past five years.